Joint Global Coordinator
Kempen & Co acted as Joint Global Coordinator in Transgene’s €34.1m capital increase
Transgene is a French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilise viral vector technology with the goal of indirectly or directly killing cancerous cells. The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualised therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: